Will Combining NK Cells From a Parent With a Humanized Antibody Be More Effective in Treating Neuroblastoma and Osteosarcoma?

Solving Kids’ Cancer supported this trial because researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for killing the cancer cells. Project Title: hu14.18/IL-2 + KIR ligand mismatch natural killer cells Researcher:…

Read More

Can T-Cells Be Engineered to Attack More Types of Pediatric Solid Tumors?

Researchers optimized the activity of a CAR (chimeric antigen receptor) constructed that targets GD2, an antigen on the surface of neuroblastoma to modify T cells for use in a future clinical trial. Project Title: Adoptive Cell Therapy for Adolescent/Pediatric Solid Tumors: Part I Researcher: Rimas Orentas, PhD Institution: National Cancer Institute Pediatric Oncology Branch Study…

Read More

Can We Train a Child’s Immune Cells to Recognize and Kill Cancer Cells?

Solving Kids’ Cancer supported this vaccine clinical trial that uses the cancer drug decitabine to help the immune cells better recognize and kill the cancer cells. Project Title: Combining Decitabine and Vaccine Therapy for Patients with Relapsed Neuroblastoma and Sarcoma Researcher: Kenneth Lucas, MD Institutions: University of Louisville Study Type: Phase I clinical trial Status:…

Read More

Can We Kill Cancer Cells Using a New Drug That Stops DNA Repair?

Solving Kids’ Cancer created this research project to test CHK1 inhibitors in neuroblastoma and medulloblastoma. After this research was complete, a phase I clinical trial for children with the best approach was planned and is now underway. Project Title: CHK1 Inhibition as Therapeutic Strategy for Children with Neuroblastoma and Medulloblastoma Researcher: Kristina Cole, MD, PhD…

Read More

What Drugs Will Target Cancer Stem Cells?

Solving Kids’ Cancer created this program to identify new promising agents for these kids. Researchers were able to successfully isolate populations of neuroblastoma cells with the properties of cancer stem cells Project Title: Drug Development Program for Neuroblastoma Stem Cells Researcher: David Kaplan, PhD Institution: The Hospital for Sick Children Study Type: Preclinical Status: Completed…

Read More

By Engineering a Herpes Virus, Can We Target Tumor Cells?

HSV1716 (Seprehvir) is a “first in class” engineered oncolytic virus derived from the herpes simplex virus, and is designed to target and destroy cancer cells. Solving Kids’ Cancer brought this cutting-edge research to the U.S. and developed the first clinical trial for children in 2010. Project Title: Dose Escalation Study of Intratumoral Herpes Simplex Virus-1…

Read More

Which Virus is Most Effective at Killing Cancer Cells?

Solving Kids’ Cancer developed a novel program to harness cutting-edge technology to identify more promising viruses. Project Title: Oncolytic Virus Development Program for Neuroblastoma Researcher: David Stojdl, PhD Institution: Children’s Hospital of Eastern Ontario Research Institute Study Type: Preclinical Status: Completed There are types of viruses that have the potential to kill cancer cells while…

Read More